221 related articles for article (PubMed ID: 20460521)
21. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
[TBL] [Abstract][Full Text] [Related]
22. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
[TBL] [Abstract][Full Text] [Related]
23. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.
Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614
[TBL] [Abstract][Full Text] [Related]
25. Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer.
Wan X; Min Y; Bludau H; Keith A; Sheiko SS; Jordan R; Wang AZ; Sokolsky-Papkov M; Kabanov AV
ACS Nano; 2018 Mar; 12(3):2426-2439. PubMed ID: 29533606
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
[TBL] [Abstract][Full Text] [Related]
28. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
29. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Guo B; Wei J; Wang J; Sun Y; Yuan J; Zhong Z; Meng F
Acta Biomater; 2022 Jun; 145():200-209. PubMed ID: 35430336
[TBL] [Abstract][Full Text] [Related]
30. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
31. Intermolecular Interactions between Coencapsulated Drugs Inhibit Drug Crystallization and Enhance Colloidal Stability of Polymeric Micelles.
Zhang L; Sun H; Chen Z; Liu Z; Huang N; Qian F
Mol Pharm; 2017 Oct; 14(10):3568-3576. PubMed ID: 28829143
[TBL] [Abstract][Full Text] [Related]
32. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
33. Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
Wu X; Kasselouri A; Vergnaud-Gauduchon J; Rosilio V
Int J Pharm; 2020 Apr; 579():119168. PubMed ID: 32087264
[TBL] [Abstract][Full Text] [Related]
34. Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers.
Song W; Li M; Tang Z; Li Q; Yang Y; Liu H; Duan T; Hong H; Chen X
Macromol Biosci; 2012 Nov; 12(11):1514-23. PubMed ID: 23070837
[TBL] [Abstract][Full Text] [Related]
35. β-Lapachone, an NQO1 bioactivatable drug, prevents lung tumorigenesis in mice.
Chen Y; Wu R; Li X; Cao M; Yang M; Fu B; Xuan C; Chen C; Zhou Y; Hu R
Eur J Pharmacol; 2024 Jun; 973():176511. PubMed ID: 38604545
[TBL] [Abstract][Full Text] [Related]
36. Construction of An Orthotopic Xenograft Model of Non-small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities.
Xu Z; Huang Y; Zhu Y; Pei X; Lu Y; Zhao S; Guo X
J Vis Exp; 2024 May; (207):. PubMed ID: 38801268
[TBL] [Abstract][Full Text] [Related]
37. Optimization and anticancer activity in vitro and in vivo of baohuoside I incorporated into mixed micelles based on lecithin and Solutol HS 15.
Yan HM; Song J; Zhang ZH; Jia XB
Drug Deliv; 2016 Oct; 23(8):2911-2918. PubMed ID: 26644047
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of 3-(1-benzotriazole)-nor-β-lapachones as NQO1-directed antitumor agents.
Wu LQ; Ma X; Liu ZP
Bioorg Chem; 2021 Aug; 113():104995. PubMed ID: 34034133
[TBL] [Abstract][Full Text] [Related]
39. 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Zhang X; Bian J; Li X; Wu X; Dong Y; You Q
Eur J Med Chem; 2017 Sep; 138():616-629. PubMed ID: 28710963
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
